ZA962891B - Oxgenated-heterocycle containing sulfonamide inhibitors of aspartyl protease - Google Patents

Oxgenated-heterocycle containing sulfonamide inhibitors of aspartyl protease

Info

Publication number
ZA962891B
ZA962891B ZA962891A ZA962891A ZA962891B ZA 962891 B ZA962891 B ZA 962891B ZA 962891 A ZA962891 A ZA 962891A ZA 962891 A ZA962891 A ZA 962891A ZA 962891 B ZA962891 B ZA 962891B
Authority
ZA
South Africa
Prior art keywords
oxgenated
heterocycle containing
aspartyl protease
containing sulfonamide
sulfonamide inhibitors
Prior art date
Application number
ZA962891A
Other languages
English (en)
Inventor
Roger D Tung
Govinda Rao Bhisetti
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ZA962891B publication Critical patent/ZA962891B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/36—Alkylene carbonates; Substituted alkylene carbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
ZA962891A 1995-04-19 1996-04-11 Oxgenated-heterocycle containing sulfonamide inhibitors of aspartyl protease ZA962891B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/424,810 US5691372A (en) 1995-04-19 1995-04-19 Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease

Publications (1)

Publication Number Publication Date
ZA962891B true ZA962891B (en) 1996-10-15

Family

ID=23683966

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA962891A ZA962891B (en) 1995-04-19 1996-04-11 Oxgenated-heterocycle containing sulfonamide inhibitors of aspartyl protease

Country Status (35)

Country Link
US (2) US5691372A (de)
EP (3) EP1637528B1 (de)
JP (1) JP4240532B2 (de)
KR (1) KR100485237B1 (de)
CN (1) CN1110491C (de)
AP (2) AP9600827A0 (de)
AR (1) AR004663A1 (de)
AT (3) ATE314360T1 (de)
AU (1) AU712913B2 (de)
BG (1) BG102041A (de)
BR (1) BR9608033A (de)
CA (1) CA2217745C (de)
CO (1) CO4700433A1 (de)
CZ (1) CZ329497A3 (de)
DE (3) DE69618779T2 (de)
DK (1) DK0833826T3 (de)
EA (1) EA000906B1 (de)
EE (1) EE9700254A (de)
ES (3) ES2171670T3 (de)
GE (1) GEP20001915B (de)
HK (2) HK1092791A1 (de)
HU (1) HUP9801948A3 (de)
IL (1) IL117962A0 (de)
IS (1) IS4575A (de)
MY (1) MY115797A (de)
NO (1) NO974744D0 (de)
NZ (1) NZ307342A (de)
PE (1) PE43697A1 (de)
PL (1) PL322904A1 (de)
PT (1) PT833826E (de)
SK (1) SK143097A3 (de)
TR (1) TR199701194T1 (de)
TW (1) TW404945B (de)
WO (1) WO1996033187A1 (de)
ZA (1) ZA962891B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US5843946A (en) 1992-08-25 1998-12-01 G.D. Searle & Co. α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5874449A (en) * 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
EA002593B1 (ru) * 1996-12-31 2002-06-27 Гилфорд Фармасьютикалз Инк. N-связанные сульфонамиды гетероциклических тиоэфиров
BR9809124A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AP2000001856A0 (en) * 1997-12-24 2000-09-30 Vertex Pharma Prodrugs of aspartyl protease inhibitors.
EP1086076B1 (de) 1998-06-19 2004-12-22 Vertex Pharmaceuticals Incorporated Sulfonamide als aspartyl-protease-inhibitoren
CA2336160C (en) 1998-06-23 2015-02-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of compounds for treating hiv
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
TWI260322B (en) 1999-02-12 2006-08-21 Vertex Pharma Inhibitors of aspartyl protease
SI1159278T1 (sl) * 1999-02-12 2006-06-30 Vertex Pharma Inhibitorji aspartil proteaze
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
AP1459A (en) * 1999-10-06 2005-08-22 Tibotec Pharm Ltd Hexahydrofuro [2,3-b] furan-3- YL-N-{3-[(1,3- benzodioxol-5- ylsufonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor.
HUP0302631A2 (hu) 2000-03-30 2003-11-28 Bristol-Myers Squibb Co. Stavudint tartalmazó elnyújtott hatóanyag-kibocsátású szemcsék
NZ528954A (en) * 2001-04-09 2005-04-29 Tibotec Pharm Ltd Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors
AU2003202914A1 (en) * 2002-01-07 2003-07-24 Sequoia Pharmaceuticals Broad spectrum inhibitors
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
WO2004033152A1 (en) * 2002-10-11 2004-04-22 Semplastics, L.L.C. Retaining ring for use on a carrier of a polishing apparatus
US7351738B2 (en) * 2002-11-27 2008-04-01 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1855672A4 (de) * 2005-03-11 2011-11-30 Glaxosmithkline Llc Hiv-proteasehemmer
JP2007202679A (ja) * 2006-01-31 2007-08-16 Juki Corp ミシンの糸調子装置
JP2007202833A (ja) * 2006-02-02 2007-08-16 Juki Corp ミシンの糸調子装置
US9808527B2 (en) 2006-11-21 2017-11-07 Purdue Research Foundation Methods and compositions for treating HIV infections
US20110046199A1 (en) 2008-01-17 2011-02-24 Purdue Research Foundation Small molecule inhibitors of hiv proteases
WO2010002994A1 (en) 2008-07-01 2010-01-07 Purdue Research Foundation Nonpeptide hiv-1 protease inhibitors
US8501961B2 (en) 2008-07-09 2013-08-06 Purdue Research Foundation HIV protease inhibitors and methods for using
CN105272991B (zh) * 2014-06-26 2017-11-07 成都中医药大学 一种化合物晶型
US11090030B2 (en) 2016-11-10 2021-08-17 Leltek Inc. Ultrasound apparatus and ultrasound emission method

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743722A (en) * 1971-07-14 1973-07-03 Abbott Lab Anti-coagulant isolation
FR2459235A1 (fr) * 1979-06-14 1981-01-09 Sanofi Sa Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique
JPS5946252A (ja) * 1982-09-09 1984-03-15 Dainippon Ink & Chem Inc 含フツ素アミノカルボキシレ−トおよびその製法
JPS5948449A (ja) * 1982-09-13 1984-03-19 Dainippon Ink & Chem Inc 直鎖状含フツ素アニオン化合物およびその製造方法
JPS6171830A (ja) * 1984-09-17 1986-04-12 Dainippon Ink & Chem Inc 界面活性剤組成物
US4616088A (en) * 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4629724A (en) * 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
DE3635907A1 (de) * 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
NL8800100A (nl) * 1987-01-21 1988-08-16 Sandoz Ag Nieuwe peptidederivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91780A (en) * 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
WO1990007330A1 (en) * 1989-01-06 1990-07-12 The Regents Of The University Of California Selection method for specific useful pharmaceutical compounds
US5151438A (en) * 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
IE902295A1 (en) * 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
WO1991018866A2 (en) * 1990-06-01 1991-12-12 The Du Pont Merck Pharmaceutical Company 1,4-diamino-2,3-dihydroxybutanes
TW225540B (de) * 1990-06-28 1994-06-21 Shionogi & Co
EP0558673B1 (de) * 1990-11-19 1996-04-17 Monsanto Company Retrovirale proteaseinhibitoren
EP0558603B1 (de) * 1990-11-19 1998-08-26 Monsanto Company Retrovirale protease inhibitoren
CA2096408C (en) * 1990-11-19 2005-02-08 Gary Anthony Decrescenzo Retroviral protease inhibitors
DE69132423T2 (de) * 1990-11-19 2001-04-26 Monsanto Co Inhibitoren retroviraler Proteasen
IE913840A1 (en) * 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
SG52731A1 (en) * 1991-11-08 1998-09-28 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids
ATE141265T1 (de) * 1992-05-20 1996-08-15 Searle & Co Verfahren zur herstellung von intermediaten in der synthese von retroviralen protease inhibitoren
EP0641325B1 (de) * 1992-05-21 2001-03-07 Monsanto Company Inhibitoren retroviraler proteasen
DE69311810T2 (de) * 1992-08-25 1997-11-27 Searle & Co N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren
CA2140928C (en) * 1992-08-25 2008-01-29 Michael L. Vazquez Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5843946A (en) * 1992-08-25 1998-12-01 G.D. Searle & Co. α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
ES2196436T3 (es) * 1992-10-30 2003-12-16 Searle & Co Acidos sulfonilalcanoilamino-hidroxietilamino-sulfamicos utiles como inhibidores de proteasas retrovirales.
ATE211462T1 (de) * 1992-10-30 2002-01-15 Searle & Co N-substituierte hydroxyethylaminosulfamidsäure- derivate verwendbar als inhibitoren retroviraler proteasen
WO1994018192A1 (en) * 1993-02-12 1994-08-18 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
TW281669B (de) * 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
ATE174587T1 (de) * 1993-08-24 1999-01-15 Searle & Co Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій

Also Published As

Publication number Publication date
EP1136479B1 (de) 2005-12-28
CA2217745A1 (en) 1996-10-24
ATE314360T1 (de) 2006-01-15
HK1092791A1 (en) 2007-02-16
PT833826E (pt) 2002-06-28
PE43697A1 (es) 1997-10-11
ES2351970T3 (es) 2011-02-14
ES2171670T3 (es) 2002-09-16
AP9600827A0 (en) 1997-10-17
BG102041A (en) 1998-09-30
MY115797A (en) 2003-09-30
WO1996033187A1 (en) 1996-10-24
ATE212344T1 (de) 2002-02-15
ES2256117T3 (es) 2006-07-16
AP9701104A0 (en) 1997-10-31
KR19990007823A (ko) 1999-01-25
DK0833826T3 (da) 2002-05-06
TW404945B (en) 2000-09-11
EP0833826A1 (de) 1998-04-08
EA199700330A1 (ru) 1998-04-30
EP1637528B1 (de) 2010-09-01
DE69618779D1 (de) 2002-03-14
DE69618779T2 (de) 2002-08-29
CN1110491C (zh) 2003-06-04
AU5665596A (en) 1996-11-07
DE69635679D1 (de) 2006-02-02
CN1184474A (zh) 1998-06-10
IL117962A0 (en) 1996-08-04
NO974744L (no) 1997-10-14
JPH11504628A (ja) 1999-04-27
EP1136479A1 (de) 2001-09-26
DE69635679T2 (de) 2006-08-31
AR004663A1 (es) 1999-03-10
EA000906B1 (ru) 2000-06-26
GEP20001915B (en) 2000-01-05
TR199701194T1 (xx) 1998-03-21
EE9700254A (et) 1998-04-15
CO4700433A1 (es) 1998-12-29
JP4240532B2 (ja) 2009-03-18
HUP9801948A3 (en) 2002-04-29
CZ329497A3 (cs) 1998-03-18
EP1637528A1 (de) 2006-03-22
IS4575A (is) 1997-10-02
CA2217745C (en) 2011-07-05
EP0833826B1 (de) 2002-01-23
SK143097A3 (en) 1998-03-04
US5691372A (en) 1997-11-25
US5990155A (en) 1999-11-23
HUP9801948A2 (hu) 1999-09-28
PL322904A1 (en) 1998-03-02
AP862A (en) 2000-08-04
DE69638252D1 (de) 2010-10-14
NO974744D0 (no) 1997-10-14
ATE479674T1 (de) 2010-09-15
AU712913B2 (en) 1999-11-18
HK1009811A1 (en) 1999-06-11
BR9608033A (pt) 1999-01-12
NZ307342A (en) 1999-04-29
KR100485237B1 (ko) 2005-09-30

Similar Documents

Publication Publication Date Title
HK1092791A1 (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
AP9701119A0 (en) THF-containing sulfonamide inhibitors of aspartyl protease
AP9300572A0 (en) Novel sulfonamide inhibitors of aspartyl protease
AP2000002023A0 (en) Sulfonamide inhibitors of aspartyl protease
ZA939285B (en) Inhibitors of aspartyl protease
PL323710A1 (en) Reversible inhibitors of cysteinic protease
HUP9902083A3 (en) Sulfonamide inhibitors of matrix metalloproteinases
PL314838A1 (en) Inhibitors of bp-iv-serine protease
PL326508A1 (en) Protease inhibitors
IL128378A0 (en) Inhibitors of cysteine protease
HUP0101831A3 (en) Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors and medicaments containing them
EP0923535A4 (de) Inhibitoren der cystein-protease
PL328665A1 (en) Inhibitors of serinic protease
AP9700961A0 (en) Aspartyl protease inhibitors
GB2299583B (en) Peptidyl inhibitors of serine proteases
HK1042892A1 (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
SI0846110T1 (en) Thf-containing sulfonamide inhibitors of aspartyl protease
ZA938470B (en) Sulfonamide inhibitors of aspartyl protease
ZA969078B (en) Inhibitors of cysteine protease.
SI0874836T1 (en) Sulfonamide inhibitors of matrix metalloproteinases
GB9521813D0 (en) Peptide inhibitors of serine proteinases
GB9500946D0 (en) Protease inhibitors
SI0936912T1 (en) Inhibitors of cysteine protease